CompletedEUCTR 2007-001060-80
A multicenter, parallel-group, double-blind, randomized, placebo-controlled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in pat...
This historical record does not confirm current site availability.
Historical research recordItalyAnxiety
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Italy
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- ABIOGEN PHARMA
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Italy
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2007-001060-80
- Official title
Show the full official title
A multicenter, parallel-group, double-blind, randomized, placebo-controlled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in pat...
Get this study by email
Recruitment & locations
CompletedItaly
Registry details
Historical country statuses
- Italy — Completed
Questions about this study
Who is behind this study?
The study sponsor is ABIOGEN PHARMA, a pharmaceutical company.
Want to explore more studies?
Explore studiesRelated studies
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER (GAD) SWITCHING FROM BENZODIAZEPINE THERAPY Estudio multicéntrico, alea...
An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...